Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines focusing on central nervous system disorders. The company has a portfolio of product including its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors.

AeroVironment designs, develops, produces, supports and operates a portfolio of products and services for government agencies and businesses. The company supplies unmanned aircraft systems (UAS) and related services primarily to organizations within the U.S. Department of Defense and to international allied governments, and tactical missile systems and related services. The company's UAS business focuses primarily on the design, development, production, marketing, support and operation of UAS and tactical missile systems and the delivery of UAS-related services that provide situational awareness, remote sensing, multi-band communications, force protection and other information and mission effects.

AudioCodes designs, develops and sells products and services for voice and data over packet networks. Voice over packet, or VoP, networks consist of key network elements such as software switches, application servers, Internet protocol (IP) phones, media gateways and session border controllers (SBC). Co.'s products primarily provide the media gateway and SBC element in the network, as well as voice over Internet protocol, or VoIP, end-points such as IP Phones and VoIP mobile clients. Multi-service business routers integrate media gateway functionality with data routing and network access. The media gateways connect legacy and IP networks.

Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for people living with neurological and neurodegenerative diseases as well as related therapeutic adjacencies. The company's main growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis; movement disorders, including Parkinson's disease; and ophthalmology. The company's marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis.

BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company's commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company's products are sold worldwide, primarily to wholesalers, specialty distributors, retail pharmacies, hospitals, government entities and the medical profession. The company manufactures products in the United States and Puerto Rico and has manufacturing operations in two foreign countries. The company has products in the following therapeutic classes: hematology, oncology, cardiovascular and immunology. The company's pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics.

Cameco and its subsidiaries are engaged in the exploration for and the development, mining, refining, conversion and fabrication of uranium for sale as fuel for generating electricity in nuclear power reactors in Canada and other countries. Co. has three reportable segments: uranium, which explores for, mines, mills, purchases, and sells uranium concentrate; fuel services, which refines, converts and fabricates uranium concentrate, and purchases and sells conversion services; and electricity, which generates and sells electricity through its 31.6% interest in the Bruce Power Limited Partnership, which operates four nuclear reactors and manages the overall site in southern Ontario.

Cardinal Health is a healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. The company's segments include: Pharmaceutical and Medical. The company's Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. The company's Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets.

Catalent is a holding company. Through its subsidiaries, the company is a provider of delivery technologies and development solutions for drugs, biologics and consumer health products. The company operates in four segments: Softgel Technologies, which provides formulation, development and manufacturing services for soft capsules; Biologics and Specialty Drug Delivery, which provides drug substance development and manufacturing; Oral Drug Delivery, which provides various formulation development and manufacturing technologies; and Clinical Supply Services, which provides manufacturing, packaging, storage, distribution, project management, and inventory management for drugs and biologics in clinical trials.

Cisco Systems designs and sells a range of technologies that power the Internet. The company's business is organized into the following three geographic segments: Americas; Europe, Middle East, and Africa; and Asia Pacific, Japan, and China. The company's products and technologies are grouped into the following categories: Infrastructure Platforms; Applications; Security and Other Products. In addition to its product offerings, the company provides a range of service offerings, including technical support services and other services. The company delivers its technologies through software and services. The company's customers include businesses of all sizes, public institutions, governments, and service providers.

Cytosorbents is engaged in critical care immunotherapy, investigating and commercializing its CytoSorb blood purification technology to reduce uncontrolled inflammation in hospitalized patients around the world, to prevent or treat multiple organ failure in life-threatening illnesses and cardiac surgery. CytoSorb, the company's primary product, is approved in the European Union as an extracorporeal cytokine filter and is designed to reduce the cytokine storm that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. CytoSorb is used during and after cardiac surgery.

DSP Group is a provider of wireless and audio chipsets for a range of smart-enabled devices. The company provides a portfolio of wireless chipsets, including DECT/CAT-iq, ULE, Wi-Fi, PSTN, HDClear?, video and Voice-over-IP (VoIP) technologies. The company is engaged in low-power integrated circuits for audio and voice signal processing applications. The company enables converged voice, audio, video and data connectivity across mobile, consumer and enterprise products, from mobile phones, Internet of Things and wearable devices, connected multimedia screens and home automation and security to cordless phones, VoIP systems and home gateways.

Exponent is a science and engineering consulting firm. The company serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation and other sectors of the economy. The company's service offerings are provided on a project-by-project basis. The company has two segments: Engineering and Other Scientific, which is a service group providing technical consulting in different practices primarily in engineering; and Environmental and Health, which provides a range of consulting services relating to environmental hazards and risks and the effect on both human health and the environment.

FutureFuel, through its subsidiary, FutureFuel Chemical Company, manufactures various chemical products, bio-based products comprised of biofuels, and bio-based specialty chemical products. The company has two reporting segments: chemicals and biofuels. The company's chemicals segment manufactures chemical products that are sold to third party customers, and comprises two components: custom manufacturing (manufacturing chemicals for certain customers) and performance chemicals (multi-customer specialty chemicals). The company's biofuels segment primarily produces and sells biodiesel to its customers. In addition, the company sells petrodiesel in blends with its biodiesel and, from time to time, with no biodiesel added.

Graco is a manufacturing company. The company designs, manufactures and markets systems and equipment used to move, measure, control, dispense and spray fluid and powder materials. The company classifies its business into three segments: Industrial, which includes its Industrial Products and Applied Fluid Technologies divisions and markets equipment and solutions for moving and applying paints, coatings, sealants, adhesives and other fluids; Process, which includes its Process, Oil and Natural Gas, and Lubrication divisions and markets pumps, valves, meters and accessories; and Contractor, which markets sprayers for architectural coatings for painting, corrosion control, texture and line striping.

Hill-Rom Holdings is a medical technology company. The company's reportable segments are: Patient Support Systems, which include a variety of frames and surfaces (such as medical surgical (med-surg) beds, intensive care unit beds, and bariatric patient beds), patient mobility solutions (such as lifts and other devices used to move patients), non-invasive therapeutic products and surfaces, and its information technologies and software solutions; Front Line Care, which includes its patient monitoring and diagnostics products and its respiratory health products; and Surgical Solutions, which include tables, lights, and pendants utilized within the surgical setting.

IDEX is an applied solutions business that sells pumps, valves, flow meters and other fluidics systems and components and engineered products. The company's segments are: Fluid and Metering Technologies, which designs, produces and distributes positive displacement pumps, flow meters, injectors and other fluid-handling pump modules and systems; Health and Science Technologies, which designs, produces and distributes fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems; and Fire and Safety/Diversified Products, which designs, produces and distributes firefighting pumps, valves and controls, rescue tools, and lifting bags.

Inphi is a provider of analog and mixed signal semiconductor solutions for the communications and datacenter markets. The company's analog and mixed signal semiconductor solutions provide an interface between analog and mixed signals and digital information in systems such as telecommunications transport systems, enterprise networking equipment and datacenters. The company has a range of products in its portfolio, including products that have commercially shipped, products for which the company has shipped engineering samples and products under development, that perform a range of functions such as amplifying, encoding, multiplexing, demultiplexing, and retiming signals at speeds up to 400 Gbps.

Intel is a data-centric company. The company's operating segments are: Data Center Group, which develops platforms for compute, storage, and network functions; Internet of Things Group, which facilitates its customers creating, storing, and processing data; Mobileye, which provides assistance and automation solutions; Non-Volatile Memory Solutions Group, which provides memory and storage products based on Intel? Optane? technology and Intel? 3D NAND technology; Programmable Solutions Group, which provides programmable semiconductors; and Client Computing Group, which connects people to data, allowing each person to focus, create, and engage in ways that unlock their individual potential.

Sanfilippo (John B.) & Son is a processor and distributor of tree nuts and peanuts. The company's principal products are raw and processed nuts. The nut product line includes almonds, pecans, peanuts, black walnuts, English walnuts, cashews, macadamia nuts, pistachios, pine nuts, Brazil nuts and filberts. The company also markets and distributes, and in various cases processes and manufactures, other food and snack products. These other products include snack mixes, salad toppings, snacks, dried fruit and chocolate and yogurt coated products; baking ingredients; bulk food products; sunflower kernels, pepitas, snack mixes, candy and confections, corn snacks, sesame sticks and other sesame snack products.

Mondelez International sells food and beverage products. The company makes and sells primarily snacks, including biscuits (cookies, crackers and salted snacks), chocolate, gum and candy, as well as various cheese and grocery and powdered beverage products. The company's portfolio includes snack brands such as Cadbury, Milka and Toblerone chocolate; Oreo, belVita and LU biscuits; Halls candy; Trident gum and Tang powdered beverages. The company's operations and management structure are organized into four operating segments: Latin America; Asia, Middle East and Africa; Europe; and North America. The company sells its products to supermarket chains, wholesalers, supercenters, value stores and other retail food outlets.

Neogen develops, manufactures, and markets a line of products for food and animal safety. The company's segments are: Food Safety, which is engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation; and Animal Safety, which is engaged in the development, production and marketing of products dedicated to animal safety, including a range of consumable products marketed to veterinarians and animal health product distributors, and provides genomic identification and related interpretive bioinformatic services.

Novavax is a late-stage biotechnology company focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases. The company's vaccine candidates, including its primary candidates, ResVax? and NanoFlu?, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. The company's product pipeline targets a variety of infectious diseases. The company is also developing immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company's primary adjuvant, Matrix-M?, has been shown to improve immune responses and was well-tolerated in multiple clinical trials.

OraSure Technologies is engaged in two principal segments. The first is the company's OSUR business, which consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its proprietary technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The second segment is the company's DNAG or molecular products and services business and is operated primarily through its subsidiaries. In the DNAG business, the company manufactures and sells kits that are used to collect, stabilize, transport and store biological samples of genetic material for molecular testing.

Owens & Minor is a healthcare solutions company. The company provides products and services to healthcare provider, manufacturers and directly to patients across the continuum of care. The company has two segments: Global Solutions, which provides a portfolio of medical and surgical supplies and service offerings to healthcare providers including supplier management, analytics, inventory management, and clinical supply management; and Global Products, which manufactures and sources medical surgical products through its production and kitting operations as well as provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels.

Quidel is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The company provides diagnostic testing solutions under various brand names, including, among others, the following: Quidel?, QuickVue?, QuickVue+?, Sofia?, Triage?, AmpliVue?, Solana?, Virena?, MicroVue?, Lyra?, FreshCells?, D3?, FastPoint?, ReadyCells?, Super E-Mix?, InflammaDry?, AdenoPlus?, ELVIRA?, ELVIS? and Thyretain?. The company's diagnostic testing solutions are separated into its four product categories: rapid immunoassay, cardiac immunoassay, specialized diagnostic solutions and molecular diagnostic solutions.

Sharps Compliance is a healthcare waste management provider focusing on regulated waste streams including medical, pharmaceutical and hazardous. The company's primary solutions include: Sharps Recovery System?, which is a solution for the containment, transportation, treatment and tracking of regulated medical waste generated outside the hospital and health care facility setting; TakeAway Medication Recovery System?, which facilitates the disposal of unused medications (including controlled substances) from users; and Universal Waste Shipback Systems, which is a jointly-promoted program for the collection, transportation and recycling of light bulbs, batteries and other mercury-containing devices.

Tyler Technologies provides information management solutions and services for the public sector. The company has two segments: Enterprise Software, which provides public sector entities with software systems and services to meet their information technology and automation needs for back-office functions such as financial management and education, courts and justice, planning, regulatory and maintenance, data and insights and case management and business management processes; and Appraisal and Tax, which provides systems and software that automate the appraisal and assessment of real and personal property as well as property appraisal outsourcing services for governments and taxing authorities.

Vapotherm is a medical technology company focused on the development and commercialization of its proprietary Hi-VNI Technology products that are used to treat patients of all ages suffering from respiratory distress. The company's Hi-VNI Technology delivers non-invasive ventilatory support by providing heated, humidified and oxygenated air at a high velocity to patients through a small-bore nasal interface. The company provides four versions of its Precision Flow systems: Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. The company's companion products include: Vapotherm Transfer Unit 2.0, the Q50 compressor, the aerosol aeroneb adaptor, and a tracheostomy adaptor.

Vertex Pharmaceuticals is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and developing research and development programs in other indications. The company's marketed products are TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat patients with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. The company is evaluating CTX001, a genetic therapy as a potential treatment for sickle cell disease and beta-thalassemia.